Toxicity reporting consistency and subjective minimizing language use in colorectal cancer (CRC) and pancreatic cancer (PaC) clinical trials: A systematic review of phase III randomized controlled trials (RCTs) presented at ASCO between 2012-2022.

Authors

null

James Yu

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

James Yu , Turab J Mohammed , Benjamin Chin-Yee , Clarissa Skorupski , Bishal Gyawali , Gary H. Lyman , Lauren Adkins , Lisa K. Hicks , Nicole M. Kuderer

Organizations

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, Moffitt Cancer Center and Research Institute, Tampa, FL, London Health Sciences Centre & Schulich School of Medicine, London, ON, Canada, University of Toronto, Toronto, ON, Canada, Queen's University, Kingston, ON, Canada, Fred Hutchinson Cancer Center, Seattle, WA, St. Michael's Hospital, Division of Hematology/Oncology; Faculty of Medicine, University of Toronto, Toronto, ON, Canada, Advanced Cancer Research Group, Kirkland, WA

Research Funding

No funding received
None.

Background: Objective and complete toxicity reporting in clinical trials is critical for patient-centered shared decision-making. Conference abstracts inform initial impressions of practice-changing treatments. Methods: We performed a systematic review of all abstracts of CRC and PaC phase 3 RCTs presented at ASCO annual meetings between 2012 – 2022; long-term follow-up, supportive care, and solely non-pharmacological studies were excluded. Objective minimization of adverse event (AE) reporting was defined as absent and/or incomplete reporting of cumulative grade 3-5 CTCAE (common terminology criteria for AE). We also assessed the use of subjective minimizing language (Chin-Yee et al ASH 2022), defined as use of “acceptable,”“tolerable”, “manageable”, “favorable” (primary minimization terms), or “feasible”, “safe”, “patients did well”, “limited” (secondary minimization terms), terms that falsely imply patients deemed the therapy as such. Presence/absence of PRO or QOL data was also assessed. Results: 63 RCTs met entry criteria (42 CRC, 21 PaC), detailed in Table. Most trials studied chemotherapy +/- other drugs (52; 83%). 17% of all abstracts did not provide any information on AE. Quantitative data on AEs were reported by 38 (60%) of abstracts. However, serious AE reporting was frequently absent (Table), with some trials reporting only specific toxicities (e.g. cytopenias) instead of cumulative CTCAE. Only 7 (11%) of abstracts noted the occurrence or absence of fatal AE. Any subjective-minimizing language was used in 15 (24%) abstracts. Notably, none of the abstracts using subjective-minimizing language provided information on fatal AE rates, nor reported on the patient perspective via QOL or PRO. Average grade ≥ 3 AE in the experimental arm were similar in abstracts with vs without minimizing language (44% vs 45%). Conclusions: Our systematic review of ph 3 RCTs in GI oncology presented at ASCO annual meetings reveals that subjective minimizing language is often used to describe serious toxicities, and without formally assessing the patient voice. Serious AE reporting is frequently absent or incomplete.

No. of abstracts63 (Total)42 (CRC)21 (PaC)
No. of Pts, Mean (Range)621 (40 - 6088)719 (108-6088)425 (40-1062)
Absent AE Reporting, No. (%)11 (17%)7 (17%)4 (19%)
Absent Fatal AE reporting56 (89%)37 (88%)19 (90%)
Absent Grade ≥ 3 CTCAE reporting48 (76%)30 (71%)18 (86%)
Use of any subjective minimizing language15 (24%)8 (19%)7 (33%)
Primary terms use13 (21%)8 (19%)5 (24%)
Secondary term use4 (6%)2 (5%)2 (10%)
Multiple minimization terms use4 (6%)3 (7%)1 (5%)
Combined Subjective or Objective Toxicity minimization60 (95%)41 (98%)19 (90%)

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Care Delivery and Regulatory Policy

Track

Care Delivery and Quality Care

Sub Track

Clinical Research Design

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 1567)

DOI

10.1200/JCO.2023.41.16_suppl.1567

Abstract #

1567

Poster Bd #

161

Abstract Disclosures

Similar Abstracts

Abstract

2024 ASCO Annual Meeting

Cost effectiveness of colorectal cancer screening in the Dominican Republic.

First Author: Yoanna S. Pumpalova

Abstract

2023 ASCO Annual Meeting

Endpoints reported in phase 3 randomized clinical trials at ASCO 2022.

First Author: Laure-Anne Marie Nicole Teuwen

First Author: Ahsan Ayaz